Financial Performance - For the first half of 2023, the company's operating revenue was CNY 2,306,140,255.48, a decrease of 16.66% compared to CNY 2,767,031,431.20 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 237,366,332.46, down 12.60% from CNY 271,574,153.43 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 223,033,561.78, a decline of 21.20% compared to CNY 283,036,443.39 in the same period last year[20]. - The company's revenue for the reporting period decreased by 59.43% year-on-year to 490 million RMB, primarily due to a decline in sales of isolation protective products[23]. - Excluding isolation protective products, the company's revenue increased by 16.51% year-on-year to 1.816 billion RMB[23]. - Basic and diluted earnings per share decreased compared to the same period last year, primarily due to reduced operating profit and an increase in total share capital from a previous private placement[23]. - The weighted average return on equity decreased compared to the same period last year, influenced by reduced operating profit and increased net assets from the previous private placement[23]. - The company achieved operating revenue of 2.306 billion yuan in the first half of 2023, a decrease of 16.66% year-on-year[55]. - Revenue from isolation protective products was 490 million yuan, down 59.43% year-on-year, while revenue excluding these products was 1.816 billion yuan, an increase of 16.51%[55]. - The net profit attributable to the parent company was 237 million yuan, a decrease of 12.60% year-on-year, and the net profit after deducting non-recurring gains and losses was 223 million yuan, down 21.20%[55]. Cash Flow and Assets - The net cash flow from operating activities increased by 48.43% to CNY 126,565,040.56, compared to CNY 85,271,465.41 in the previous year[20]. - The total assets at the end of the reporting period were CNY 8,177,277,700.20, reflecting a 3.55% increase from CNY 7,896,933,885.12 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were CNY 5,616,117,983.67, up 1.34% from CNY 5,541,678,060.39 at the end of the previous year[20]. - The company's cash and cash equivalents decreased by 20.15% to ¥1,656,921,010.13, accounting for 20.26% of total assets[70]. - The company's total liabilities rose to RMB 2,329,678,225.99 from RMB 2,139,939,039.32, marking an increase of approximately 8.85%[149]. - The company's equity attributable to shareholders increased to RMB 5,616,117,983.67 from RMB 5,541,678,060.39, a growth of about 1.35%[149]. Market Presence and Strategy - The company has established a marketing network covering over 8,000 hospitals across all provinces in China, including nearly 1,100 top-tier hospitals[28]. - The company has a strong presence in the international market, exporting to over 70 countries and regions, and has been ranked among the top three in China's medical dressing exports for several consecutive years[28]. - The company is focusing on market expansion through the development of innovative healthcare products tailored to meet the needs of various medical environments[31]. - The company is exploring potential acquisitions to strengthen its market position and broaden its product portfolio in the healthcare sector[31]. - The company is actively exploring international expansion and has plans to establish overseas bases to support future business growth[90]. Research and Development - The company plans to enhance its research and development efforts to introduce advanced wound care technologies in the upcoming fiscal year[31]. - The company established a new product development management system, enhancing R&D efficiency through structured market insights and customer demand management[62]. - Research and development expenses decreased to approximately ¥46 million, down 26.9% from ¥63 million in the first half of 2022[158]. - The company is focusing on technological innovation, collaborating with universities for advanced material development and achieving significant progress in wound care technology[61]. Regulatory and Compliance - The company is facing risks related to regulatory changes and industry policy shifts, which could adversely affect its operations if not adapted to promptly[88]. - The company has established a quality management system to mitigate risks associated with product quality, which is critical for patient safety, and will continue to enhance quality control capabilities through digital and automated processes[89]. - The company will strictly fulfill all commitments made prior to its listing, and if any commitments are not fulfilled, it will disclose the reasons in a timely manner through designated media[116]. Shareholder Information - The proposed cash dividend is CNY 7.50 per 10 shares, totaling CNY 199,741,320, which accounts for 84.15% of the net profit attributable to shareholders for the first half of 2023[5]. - The company reported a total of 26,286 common shareholders as of the end of the reporting period[135]. - Zhejiang Zhend Medical Holdings Co., Ltd. is the largest shareholder with 109,191,600 shares, accounting for 85.51% of the total shares[138]. Environmental Initiatives - The company has not faced any environmental penalties during the reporting period and is committed to green development and low-carbon initiatives[108]. - The company implemented various energy-saving measures, including the use of clean energy and optimization of production processes, to reduce carbon emissions[109]. - The company has established an ISO system for environmental management and is actively promoting energy conservation and emission reduction[108].

证券代码：603301 证券简称：振德医疗 公告编号：2023-026 振德医疗用品股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）第三届监事会 第八次会议于 2023 年 8 月 29 日以通讯方式召开，会议通知已于 2023 年 8 月 24 日以传真、E-MAIL 和专人送达等形式提交各监事。本次会 议应表决监事 3 名，实际表决监事 3 名，符合《公司法》和《公司章 程》的有关规定，决议合法有效。 《公司 2023 年半年度报告》及《公司 2023 年半年度报告摘要》 详见 2023 年 8 月 30 日上海证券交易所网站（www.sse.com.cn）。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 2、审议通过《关于公司 2023 年半年度利润分配预案》，监事会 同意公司拟以实施权益分派股权登记日登记的总股本为基数（不包括 公司回购专户的股份数量），向全体股东每 10 股派发现金红利 7.50 元（含税）。截至 202 ...

振德医疗用品股份有限公司独立董事 关于第三届董事会第十次会议相关事项的独立意见 一、关于公司 2023 年半年度利润分配预案之事项 我们认为公司拟定的 2023 年半年度利润分配预案符合有关法律、 法规和《公司章程》的相关规定，在保证公司正常经营和长远发展的 基础上，兼顾了广大股东的即期回报和长远利益，不存在损害股东特 别是中小股东利益的情况，有利于促进公司持续稳定健康发展。 我们同意公司拟定的 2023 年半年度利润分配预案，并同意提交 公司 2023 年第一次临时股东大会审议。 根据《上海证券交易所股票上市规则》、《上市公司独立董事规则》 和《公司章程》等有关规定，作为振德医疗用品股份有限公司（以下 简称"公司"）的独立董事，我们对公司第三届董事会第十次会议审 议的相关事项发表独立意见如下： 二、关于《公司 2023 年半年度募集资金存放与实际使用情况的 专项报告》之事项 经核查，公司 2023 年半年度募集资金实际存放和使用符合《上 市公司证券发行管理办法》、《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》和《上海证券交易所上市公司自律 监管指引第 1 号—规范运作》等有关法律、 ...

证券代码：603301 证券简称：振德医疗 公告编号：2023-025 振德医疗用品股份有限公司 第三届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）第三届董事会 第十次会议于 2023 年 8 月 29 日以通讯方式召开，会议通知已于 2023 年 8 月 24 日以传真、E-MAIL 和专人送达等形式提交各董事。本次会 议应表决董事 9 名，实际表决董事 9 名，符合《公司法》和《公司章 程》的有关规定，决议合法有效。 会议审议议案后形成以下决议： 1、审议通过《公司 2023 年半年度报告》 《公司 2023 年半年度报告》及《公司 2023 年半年度报告摘要》 详见 2023 年 8 月 30 日上海证券交易所网站（www.sse.com.cn）。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、审议通过《关于公司 2023 年半年度利润分配预案》，董事会 同意公司拟以实施权益分派股权登记日登记的总股本为基数（不包括 公司回购专户的股份数 ...

证券代码：603301 证券简称：振德医疗 公告编号：2023-029 振德医疗用品股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2023 年 9 月 11 日（星期一）10:00-11:00 2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2023 年 9 月 4 日（星期一） 至 9 月 8 日（星期 五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明会 上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2023 年 8 月 30 日发布公司 2023 年半年度报告。为便于广大投资者更全面深入 地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 9 月 11 日上午 10: ...

证券代码：603301 证券简称：振德医疗 公告编号：2023-028 振德医疗用品股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第一次临时股东大会 召开的日期时间：2023 年 9 月 19 日 14 点 00 分 召开地点：浙江省绍兴市越城区皋埠街道香积路 55 号振德医疗用品股份有 限公司会议室 股东大会召开日期：2023年9月19日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 19 日 至 2023 年 9 月 19 日 采用上海证券交易所网络投票系统，通过交易 ...

证券代码：603301 证券简称：振德医疗 公告编号：2023-027 振德医疗用品股份有限公司 关于公司 2023 年半年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、每股分配金额：每股派发现金红利 0.75 元（含税）。 2、本次利润分配以实施权益分派股权登记日登记的总股本扣除 公司回购专户的股份数为基数，具体日期将在权益分派实施公告中明 确。 3、在实施权益分派的股权登记日前公司总股本发生变动的，拟 维持每股分配 0.75 元（含税）不变，相应调整分配总额，并将另行 公告具体调整情况。 一、利润分配方案的具体内容 实施权益分派股权登记日,公司通过回购专用账户所持有本公司 股份，不参与本次利润分配。如在利润分配预案披露之日起至实施权 益分派股权登记日期间，若公司总股本发生变动，公司拟维持每股分 配 0.75 元（含税）不变，相应调整分配总额。如后续总股本发生变 化，将另行公告具体调整情况。 本次利润分配方案尚需提交公司 2023 年第一次临时股东大会审 议。 二、公司履行的决策程 ...

1、 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2019〕2008 号文核准， 并经上海证券交易所同意，本公司由中信证券股份有限公司作为本次 发行的保荐人和主承销商，负责本次公开发行可转换债券发行的组织 实施。本次发行的可转换公司债券向股权登记日（2019 年 12 月 18 日）收市后登记在册的公司原股东优先配售，原股东优先配售后余额 部分（含原股东放弃优先配售部分）采用网上向社会公众投资者通过 上海证券交易所交易系统发售的方式进行。本次发行可转换公司债券 4,400,000 张，每张面值为人民币 100.00 元，按面值发行，共计募 集资金人民币 44,000.00 万元，扣除保荐承销费 821.50 万元(其中， 不含税保荐承销费为人民币 775.00 万元，该部分属于发行费用；税 款为人民币 46.50 万元，该部分不属于发行费用)后实际收到的募集 资金为人民币 43,178.50 万元，已由主承销商中信证券股份有限公司 于 2019 年 12 月 25 日汇入本公司募集资金监管账户。另减除律师费、 会计师费、资信评级费、债券发行登记费和法定信息披露费等其他发 行费用(均不含税 ...

2022 可持续发展报告 暨ESG(环境、社会及治理)报告 振德医疗用品股份有限公司 目录 2022 可持续发展报告 暨 ESG（环境、社会及治理）报告 目录 | 关于本报告 | 03 | | --- | --- | | 关于振德医疗 | 04 | | 董事长致辞 | 05 | | �从 Care 到 We Care | | | 2022 年可持续发展关键绩效 | 07 | 02 可持续发展管理 | ESG 战略 | 17 | | --- | --- | | ESG 管理架构 | 19 | | 利益相关方沟通 | 19 | | 实质性议题分析 | 21 | 04 | 关爱，保障员工权益与福利 | 35 | | --- | --- | | 投入，携手员工共同成长 | 38 | | 坚守，维护员工安全与健康 | 42 | 01 责任行动 | 员工关怀 | 11 | | --- | --- | | 社区沟通 | 12 | | 社会捐赠 | 14 | 03 合规为先，勇于变革 | 规范治理，保护投资者权益 | 25 | | --- | --- | | 合规经营，恪守商业道德 | 27 | | 持续变革，谋求长久发展 ...

Financial Performance - The company's operating revenue for 2022 reached CNY 6,137,634,431.69, representing a year-on-year increase of 20.54% compared to CNY 5,091,572,447.78 in 2021[23]. - The net profit attributable to shareholders of the listed company was CNY 703,226,016.47, a significant increase of 40.09% from CNY 501,983,606.77 in the previous year[23]. - The net cash flow from operating activities increased by 52.40% to CNY 1,246,045,055.93, compared to CNY 817,629,318.83 in 2021[23]. - Total assets at the end of 2022 amounted to CNY 7,896,933,885.12, reflecting a growth of 22.97% from CNY 6,421,676,690.51 at the end of 2021[24]. - The company reported a net asset attributable to shareholders of CNY 5,541,678,060.39, which is a 36.27% increase from CNY 4,066,740,693.18 at the end of 2021[24]. - Basic earnings per share for 2022 increased by 8.71% to CNY 2.87 compared to CNY 2.64 in 2021[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 33.18% to CNY 2.97 per share in 2022 from CNY 2.23 in 2021[25]. - The gross profit margin was 35.00%, a decrease of 0.95% compared to the previous year, primarily due to the price normalization of isolation protective products[75]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 7.50 per 10 shares (including tax), totaling CNY 199,741,320 based on 266,321,760 shares[6]. - The total cash dividend amount (including tax) is CNY 312,857,887.89, which accounts for 45.93% of the net profit attributable to ordinary shareholders[182]. - The company emphasizes continuous and stable cash dividends to enhance long-term investment returns for shareholders[178]. - The cash dividend proposal is subject to approval at the 2022 annual general meeting[179]. Market and Business Expansion - The company achieved a main business revenue of 6.131 billion yuan, a year-on-year increase of 24.94%, with net profit attributable to shareholders reaching 681 million yuan, up 14.31%[37]. - Domestic main business revenue reached 4.104 billion yuan, a year-on-year increase of 90.62%, with hospital line revenue at 2.713 billion yuan, excluding isolation protective products[39]. - The company expanded its coverage to over 7,000 hospitals nationwide, an increase of nearly 1,000 hospitals compared to the beginning of the reporting period, including over 1,000 top-tier hospitals[38]. - The company’s international main business revenue was 2.027 billion yuan, a decrease of 26.40% year-on-year, primarily due to high sales of isolation protective products in the previous year[41]. - The company is focused on solidifying its management foundation and improving economic efficiency amid a complex external environment[36]. Research and Development - Research and development expenses increased by 48.23% to 227 million RMB, indicating a strong commitment to innovation[72]. - The company emphasized R&D investment, establishing a medical device industry innovation consortium to enhance technical innovation capabilities[43]. - The company has established a mechanism for intellectual property protection in the pharmaceutical procurement sector, indicating a strategic focus on compliance and innovation[104]. - The company is committed to investing in R&D, focusing on key technologies in infection control and wound care, and exploring sustainable materials for product development[129]. Acquisitions and Investments - The company acquired 100% equity of MIDMEDS LIMITED in the UK, expanding its channel coverage and enhancing its product portfolio in surgical infection control[49]. - The company completed a capital increase of 137.06 million RMB in its wholly-owned subsidiary, Shaoxing Zhend Medical Supplies Co., Ltd., maintaining 100% control[108]. - The company invested 100 million RMB in Anhui Meidis, also retaining 100% control post-capital increase[109]. - The company plans to acquire 100% equity of Jiangsu Yinbeisi Technology Development Co., Ltd. for 24.33 million Yuan, focusing on pre-filled catheter flushing products[137]. Governance and Compliance - The company’s governance practices comply with relevant laws and regulations, with no significant discrepancies noted[143]. - The company has established a comprehensive governance structure to enhance investor relations and protect minority shareholders' rights[197]. - The company has implemented measures to ensure the independence of its assets, personnel, and operations[143]. - The company’s financial resolutions and proposals for related party transactions were also approved during the annual meeting[146]. Employee and Organizational Development - The total number of employees in the parent company is 1,524, while the total number of employees in major subsidiaries is 6,961, resulting in a combined total of 8,485 employees[172]. - The company has established a competitive compensation policy that includes basic salary, performance assessment, and bonus incentives, focusing on employee performance and contributions[174]. - The company has implemented a comprehensive training program to enhance employee skills and organizational capabilities[175]. Environmental and Social Responsibility - The company has implemented internal environmental management systems, including water pollution prevention and solid waste management[194]. - The company emphasizes energy conservation and pollution reduction as part of its sustainable development strategy[197]. - The company actively participates in social responsibility initiatives, including donations of medical supplies[197].